Correspondence 0001193125-25-018390 from Aardvark Therapeutics, Inc. (AARD)
Aardvark Therapeutics, Inc.
Date: Jan. 31, 2025 · CIK: 0001774857 · Accession: 0001193125-25-018390
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-284440
Letter
Aardvark Therapeutics, Inc.
4370 La Jolla Village Drive, Suite 1050
San Diego, CA 92122
February 10,
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549-0406
Attn: Eric Atallah
Mary Mast
Tamika Sheppard
Laura Crotty
Re: Aardvark Therapeutics, Inc.
Registration Statement on Form S-1, as amended (File No. 333-284440)
Request for Acceleration of Effective Date
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Aardvark Therapeutics, Inc. (the “Company”) hereby respectfully requests that the effectiveness of the Registration Statement on Form S-1 (File No. 333-284440) of the Company, originally filed with the Securities and Exchange Commission (the “Commission”) on January 23, 2025, as amended (the “Registration Statement”), be accelerated so that such Registration Statement shall become effective at 4:00 p.m., Eastern Time, on February 12, 2025 or as soon as possible thereafter.
It would be appreciated if, promptly after the Registration Statement has become effective, you would so inform our outside counsel, Jeffrey T. Hartlin of Paul Hastings LLP, by telephone at (650) 320-1804 or by email at jeffhartlin@paulhastings.com. The Company hereby authorizes Mr. Hartlin of Paul Hastings LLP to orally modify or withdraw this request for acceleration.
Sincerely,
AARDVARK THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Aardvark Therapeutics, Inc. 4370 La Jolla Village Drive, Suite 1050 San Diego, CA 92122 February 10, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-0406 Attn: Eric Atallah Mary Mast Tamika Sheppard Laura Crotty Re: Aardvark Therapeutics, Inc. Registration Statement on Form S-1, as amended (File No. 333-284440) Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Aardvark Therapeutics, Inc. (the “Company”) hereby respectfully requests that the effectiveness of the Registration Statement on Form S-1 (File No. 333-284440) of the Company, originally filed with the Securities and Exchange Commission (the “Commission”) on January 23, 2025, as amended (the “Registration Statement”), be accelerated so that such Registration Statement shall become effective at 4:00 p.m., Eastern Time, on February 12, 2025 or as soon as possible thereafter. It would be appreciated if, promptly after the Registration Statement has become effective, you would so inform our outside counsel, Jeffrey T. Hartlin of Paul Hastings LLP, by telephone at (650) 320-1804 or by email at jeffhartlin@paulhastings.com. The Company hereby authorizes Mr. Hartlin of Paul Hastings LLP to orally modify or withdraw this request for acceleration. Sincerely, AARDVARK THERAPEUTICS, INC. By: /s/ Tien-Li Lee Name: Tien-Li Lee, M.D. Title: Chief Executive Officer cc: Jeffrey T. Hartlin, Esq. (Paul Hastings LLP)